Hemolytic Uremic Syndrome As the Presenting Manifestation of WT1 Mutation and Denys-Drash Syndrome: a Case Report

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2017 Jul 20

PMID 28720077

Citations 6

Authors

Joseph L Alge

Scott E Wenderfer

John Hicks

Mir Reza Bekheirnia

Deborah A Schady

Jamey S Kain

Michael C Braun

Affiliations

Soon will be listed here.

Abstract

Background: Hemolytic uremic syndrome (HUS) can occur as a primary process due to mutations in complement genes or secondary to another underlying disease. HUS sometimes occurs in the setting of glomerular diseases, and it has been described in association with Denys-Drash syndrome (DDS), which is characterized by the triad of abnormal genitourinary development; a pathognomonic glomerulopathy, diffuse mesangial sclerosis; and the development of Wilms tumor.

Case Presentation: We report the case of a 46, XX female infant who presented with HUS and biopsy-proven thrombotic microangiopathy. Next generation sequencing of genes with known mutations causative of atypical HUS found that she was homozygous for the Complement Factor H H3 haplotype and heterozygous for a variant of unknown significance in the DGKE gene. Whole exome sequencing identified a de novo heterozygous WT1 c.1384C > T; p.R394W mutation, which is classically associated with Denys-Drash syndrome (DDS). At the time of bilateral nephrectomy five months after her initial biopsy, she had diffuse mesangial sclerosis, typical of Denys-Drash syndrome, without evidence of thrombotic microangiopathy.

Conclusion: This unique case highlights HUS as a rare but important manifestation of WT1 mutation and provides new insight into the genetics underlying this association.

Citing Articles

Association of Atypical Hemolytic Uremic Syndrome With Wilms' Tumor 1 Gene Mutations: A Case Series and Literature Review.

Al Zabali S, Alseneidi S, Faqeehi H, Albatati S, Al Anazi A Cureus. 2024; 16(9):e70016.

PMID: 39445256 PMC: 11498079. DOI: 10.7759/cureus.70016.

Initiation of metformin in early pregnancy results in fetal bioaccumulation, growth restriction, and renal dysmorphology in a primate model.

Bolte E, Dean T, Garcia B, Seferovic M, Sauter K, Hummel G Am J Obstet Gynecol. 2024; 231(3):352.e1-352.e16.

PMID: 38871238 PMC: 11344684. DOI: 10.1016/j.ajog.2024.06.002.

Lopez-Gonzalez M, Ariceta G Pediatr Nephrol. 2024; 39(9):2601-2609.

PMID: 38326647 DOI: 10.1007/s00467-024-06302-y.

WT1 complete gonadal dysgenesis with membranoproliferative glomerulonephritis: case series and literature review.

Anderson E, Aldridge M, Turner R, Harraway J, McManus S, Stewart A Pediatr Nephrol. 2022; 37(10):2369-2374.

PMID: 35211794 PMC: 9395477. DOI: 10.1007/s00467-022-05421-8.

Case Report: Denys-Drash Syndrome With Causative Variant Presenting as Atypical Hemolytic Uremic Syndrome.

Cheng C, Chen L, Wen S, Lin Z, Jiang X Front Pediatr. 2021; 8:605889.

PMID: 33392118 PMC: 7775732. DOI: 10.3389/fped.2020.605889.

References

Jeanpierre C, Denamur E, Henry I, Cabanis M, Luce S, Cecille A . Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database. Am J Hum Genet. 1998; 62(4):824-33. PMC: 1377045. DOI: 10.1086/301806. View

Hanson J, Gorman J, Reese J, Fraizer G . Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Front Biosci. 2006; 12:2279-90. PMC: 2562899. DOI: 10.2741/2230. View

Letunic I, Doerks T, Bork P . SMART: recent updates, new developments and status in 2015. Nucleic Acids Res. 2014; 43(Database issue):D257-60. PMC: 4384020. DOI: 10.1093/nar/gku949. View

Larsson S, Charlieu J, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A . Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell. 1995; 81(3):391-401. DOI: 10.1016/0092-8674(95)90392-5. View

Manenti L, Gnappi E, Vaglio A, Allegri L, Noris M, Bresin E . Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol Dial Transplant. 2013; 28(9):2246-59. DOI: 10.1093/ndt/gft220. View

Ozdemir D, Hohenstein P . Wt1 in the kidney--a tale in mouse models. Pediatr Nephrol. 2013; 29(4):687-93. DOI: 10.1007/s00467-013-2673-7. View

Little M, Holmes G, Bickmore W, Van Heyningen V, Hastie N, Wainwright B . DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Hum Mol Genet. 1995; 4(3):351-8. DOI: 10.1093/hmg/4.3.351. View

Manivel J, Sibley R, Dehner L . Complete and incomplete Drash syndrome: a clinicopathologic study of five cases of a dysontogenetic-neoplastic complex. Hum Pathol. 1987; 18(1):80-9. DOI: 10.1016/s0046-8177(87)80199-5. View

Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S . Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010; 5(10):1844-59. PMC: 2974386. DOI: 10.2215/CJN.02210310. View

10.

Mele C, Lemaire M, Iatropoulos P, Piras R, Bresin E, Bettoni S . Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. Clin J Am Soc Nephrol. 2015; 10(6):1011-9. PMC: 4455211. DOI: 10.2215/CJN.08520814. View

11.

Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang W, le Quintrec M . Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013; 45(5):531-6. PMC: 3719402. DOI: 10.1038/ng.2590. View

12.

Lee J, Imani P, Geer J, Braun M, Srivaths P, Orjuela A . The Pharmacokinetics of Intradialytic Administration of Eculizumab in an Infant. Am J Kidney Dis. 2015; 66(6):1105-6. DOI: 10.1053/j.ajkd.2015.07.028. View

13.

Noris M, Mele C, Remuzzi G . Podocyte dysfunction in atypical haemolytic uraemic syndrome. Nat Rev Nephrol. 2015; 11(4):245-52. DOI: 10.1038/nrneph.2014.250. View

14.

Gao F, Maiti S, Sun G, Ordonez N, Udtha M, Deng J . The Wt1+/R394W mouse displays glomerulosclerosis and early-onset renal failure characteristic of human Denys-Drash syndrome. Mol Cell Biol. 2004; 24(22):9899-910. PMC: 525476. DOI: 10.1128/MCB.24.22.9899-9910.2004. View

15.

Schumacher V, Jeruschke S, Eitner F, Becker J, Pitschke G, Ince Y . Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J Am Soc Nephrol. 2007; 18(3):719-29. DOI: 10.1681/ASN.2006020124. View

16.

Niaudet P, Gubler M . WT1 and glomerular diseases. Pediatr Nephrol. 2006; 21(11):1653-60. DOI: 10.1007/s00467-006-0208-1. View

17.

Pelletier J, BRUENING W, Kashtan C, MAUER S, Manivel J, Striegel J . Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell. 1991; 67(2):437-47. DOI: 10.1016/0092-8674(91)90194-4. View

18.

Ladomery M, Sommerville J, Woolner S, Slight J, Hastie N . Expression in Xenopus oocytes shows that WT1 binds transcripts in vivo, with a central role for zinc finger one. J Cell Sci. 2003; 116(Pt 8):1539-49. DOI: 10.1242/jcs.00324. View

19.

Sherbotie J, Van Heyningen V, Axton R, Williamson K, Finn L, Kaplan B . Hemolytic uremic syndrome associated with Denys-Drash syndrome. Pediatr Nephrol. 2000; 14(12):1092-7. DOI: 10.1007/s004670000389. View

20.

Denys P, Malvaux P, Van Den Berghe H, Tanghe W, Proesmans W . [Association of an anatomo-pathological syndrome of male pseudohermaphroditism, Wilms' tumor, parenchymatous nephropathy and XX/XY mosaicism]. Arch Fr Pediatr. 1967; 24(7):729-39. View